TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

By

TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

By

TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

By

Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

By

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting

By

TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors

By

TScan Therapeutics Announces CEO Transition

By

TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies

By

TScan Therapeutics to Participate in the Barclays Global Healthcare Conference

By

TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones

By